Oximeters: Prevounce Health, OxiWear enter market

INDIANAPOLIS – Prevounce Health, a provider of remote care management software, devices and services, has launched Pylo OX1-LTE, its first blood oxygen device for remote patient monitoring. OX1-LTE, which is cleared by the U.S. Food and Drug Administration and which is FCC certified, is available now for use with the Prevounce remote care management platform and seamlessly integrates with third-party health software via the Pylo cloud API. "We're excited to add OX1-LTE to the family of Pylo devices available for use in RPM programs," says Daniel Tashnek, founder and CEO of Prevounce. "After years of utilizing third-party oximeters, our team carefully designed the OX1-LTE to check every box we think providers and patients want and deserve out of a connected pulse oximeter. This translates to a best-in-class device that reliably provides actionable data to clinicians to empower their care. The OX1-LTE couldn't be simpler for patients to use, which will boost RPM program engagement and participation while reducing the clinician and technical support work required to scale remote monitoring programs." Prevounce Health says the OX1-LTE offers numerous advantages over other pulse oximeters for patients enrolled in RPM programs for chronic respiratory conditions, such as roaming on multiple cellular networks, delivering reliable connectivity and consistent, secure data transmission to patient care teams even in areas with a weak signal. The device is also cost-effective, making it easier for organizations to invest in growing their RPM programs. 

ARLINGTON, Va. – OxiWear has announced it has received clearance from the U.S. Food and Drug Administration for its oxygen monitoring device designed for continuous, real-time measurement of blood oxygen saturation and pulse rate. The company says the OxiWear’s continuous data collection capability is vital for the early detection of hypoxemia, offering prompt haptic and emergency messaging alerts that can potentially save lives. "We are thrilled to receive FDA clearance for our OxiWear device," said Shavini Fernando, CEO of OxiWear. "This validation from the FDA underscores the rigorous testing and development that our team has undertaken to ensure the highest standards of safety and efficacy. Our goal is to provide a reliable, user-friendly solution that empowers patients and supports healthcare professionals in delivering optimal care." The FDA clearance paves the way for OxiWear to expand its market share and for the company to continue its research and development efforts to expand the capabilities of its platform and address a broader range of health monitoring needs. OxiWear was developed in 2019 by Shavini Fernando, a VR/video game and web designer who suffers from pulmonary hypertension as a result of Eisenmenger's syndrome.